A Novel Prognostic Score for NSCLC following Neoadjuvant therapy

Dr. Sabina Berezowka, from the university of Lausanne Switzerland, discusses with our host her team’s recent study describing a novel “Prognostic Score” for assessing tumor regression following Neaodjuvant therapy in non-small cell lung cancer (NSCLC). The proposed combined prognostic score (PRSC) performed better than pTNM staging and previously published Major Pathologic Response (MPR) approach. Study by Berezowka et al, A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response. Modern Pathology, 34, 1333–1344, 2021. https://www.nature.com/articles/s41379-021-00777-y.